Last reviewed · How we verify
MM09 Mannosylated 10.000 sublingual
MM09 Mannosylated 10.000 sublingual is a Biologic drug developed by Inmunotek S.L.. It is currently in Phase 2 development.
MM09 is a mannosylated allergen immunotherapy under development by Inmunotek S.L. for the treatment of mite allergy-induced rhinitis/rhinoconjunctivitis. Currently in Phase 2, it aims to improve dosing and efficacy compared to existing treatments.
At a glance
| Generic name | MM09 Mannosylated 10.000 sublingual |
|---|---|
| Sponsor | Inmunotek S.L. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MM09 Mannosylated 10.000 sublingual CI brief — competitive landscape report
- MM09 Mannosylated 10.000 sublingual updates RSS · CI watch RSS
- Inmunotek S.L. portfolio CI
Frequently asked questions about MM09 Mannosylated 10.000 sublingual
What is MM09 Mannosylated 10.000 sublingual?
MM09 Mannosylated 10.000 sublingual is a Biologic drug developed by Inmunotek S.L..
Who makes MM09 Mannosylated 10.000 sublingual?
MM09 Mannosylated 10.000 sublingual is developed by Inmunotek S.L. (see full Inmunotek S.L. pipeline at /company/inmunotek-s-l).
What development phase is MM09 Mannosylated 10.000 sublingual in?
MM09 Mannosylated 10.000 sublingual is in Phase 2.